Company intelligence / Profile preview

Delphi Diagnostics

Houston, Texas, United Statesdelphi-diagnostics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Delphi Diagnostics has developed the Endocrine Activity Index (EAI) which measures endocrine transcriptional activity in Stage II-III, HR+, HER2- breast cancer patients. The test helps determine which patients will benefit most from dose-intense chemotherapy regimens. Recent data has confirmed EAI as a predictor of benefit from dose-dense chemotherapy, with findings presented at the 2024 Annual Society of Clinical Oncology Meeting[1].

Therapeutic areas: Oncology
Modalities: Diagnostic tests
Industry: Molecular Diagnostics

Drug pipeline

1 asset

FirstLook Lung

Commercial

Indications: Lung cancer screening

Partnerships

Quantum Leap Healthcare Collaborative (for I-SPY 2 TRIAL)

Beyond the preview

Go deeper on Delphi Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delphi Diagnostics.

Explore the full profile